BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Thöm I, Andritzky B, Schuch G, Burkholder I, Edler L, Johansen JS, Bokemeyer C, Schumacher U, Laack E. Elevated pretreatment serum concentration of YKL-40-An independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancer. Cancer 2010;116:4114-21. [PMID: 20564116 DOI: 10.1002/cncr.25196] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Wang D, Zhai B, Hu F, Liu C, Zhao J, Xu J. High YKL-40 serum concentration is correlated with prognosis of Chinese patients with breast cancer. PLoS One 2012;7:e51127. [PMID: 23227243 DOI: 10.1371/journal.pone.0051127] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
2 Xu CH, Yu LK, Hao KK. Serum YKL-40 level is associated with the chemotherapy response and prognosis of patients with small cell lung cancer. PLoS One 2014;9:e96384. [PMID: 24801872 DOI: 10.1371/journal.pone.0096384] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
3 Yasar O, Akcay T, Obek C, Turegun FA. Diagnostic potential of YKL-40 in bladder cancer. Urologic Oncology: Seminars and Original Investigations 2016;34:257.e19-24. [DOI: 10.1016/j.urolonc.2016.02.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
4 Xing S, Zheng X, Zeng T, Zeng MS, Zhong Q, Cao YS, Pan KL, Wei C, Hou F, Liu WL. Chitinase 3-like 1 secreted by peritumoral macrophages in esophageal squamous cell carcinoma is a favorable prognostic factor for survival. World J Gastroenterol 2017; 23(43): 7693-7704 [PMID: 29209110 DOI: 10.3748/wjg.v23.i43.7693] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
5 Qiu QC, Wang L, Jin SS, Liu GF, Liu J, Ma L, Mao RF, Ma YY, Zhao N, Chen M, Lin BY. CHI3L1 promotes tumor progression by activating TGF-β signaling pathway in hepatocellular carcinoma. Sci Rep 2018;8:15029. [PMID: 30301907 DOI: 10.1038/s41598-018-33239-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
6 Schmidt IM, Hall IE, Kale S, Lee S, He CH, Lee Y, Chupp GL, Moeckel GW, Lee CG, Elias JA, Parikh CR, Cantley LG. Chitinase-like protein Brp-39/YKL-40 modulates the renal response to ischemic injury and predicts delayed allograft function. J Am Soc Nephrol 2013;24:309-19. [PMID: 23291472 DOI: 10.1681/ASN.2012060579] [Cited by in Crossref: 75] [Cited by in F6Publishing: 49] [Article Influence: 8.3] [Reference Citation Analysis]
7 Thongsom S, Chaocharoen W, Silsirivanit A, Wongkham S, Sripa B, Choe H, Suginta W, Talabnin C. YKL-40/chitinase-3-like protein 1 is associated with poor prognosis and promotes cell growth and migration of cholangiocarcinoma. Tumour Biol. 2016;37:9451-9463. [PMID: 26781979 DOI: 10.1007/s13277-016-4838-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
8 Kim KC, Yun J, Son DJ, Kim JY, Jung JK, Choi JS, Kim YR, Song JK, Kim SY, Kang SK, Shin DH, Roh YS, Han SB, Hong JT. Suppression of metastasis through inhibition of chitinase 3-like 1 expression by miR-125a-3p-mediated up-regulation of USF1. Theranostics 2018;8:4409-28. [PMID: 30214629 DOI: 10.7150/thno.26467] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
9 Sandokji I, Greenberg JH. Plasma and Urine Biomarkers of CKD: A Review of Findings in the CKiD Study. Semin Nephrol 2021;41:416-26. [PMID: 34916002 DOI: 10.1016/j.semnephrol.2021.09.003] [Reference Citation Analysis]
10 Weng TY, Wang CY, Hung YH, Chen WC, Chen YL, Lai MD. Differential Expression Pattern of THBS1 and THBS2 in Lung Cancer: Clinical Outcome and a Systematic-Analysis of Microarray Databases. PLoS One 2016;11:e0161007. [PMID: 27513329 DOI: 10.1371/journal.pone.0161007] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
11 Zhao T, Su Z, Li Y, Zhang X, You Q. Chitinase-3 Like-protein-1 function and its role in diseases. Signal Transduct Target Ther. 2020;5:201. [PMID: 32929074 DOI: 10.1038/s41392-020-00303-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
12 Zhu CB, Chen LL, Tian JJ, Su L, Wang C, Gai ZT, Du WJ, Ma GL. Elevated serum YKL-40 level predicts poor prognosis in hepatocellular carcinoma after surgery. Ann Surg Oncol. 2012;19:817-825. [PMID: 21861215 DOI: 10.1245/s10434-011-2026-3] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 2.0] [Reference Citation Analysis]
13 Vom Dorp F, Tschirdewahn S, Niedworok C, Reis H, Krause H, Kempkensteffen C, Busch J, Kramer G, Shariat SF, Nyirady P, Rübben H, Szarvas T. Circulating and Tissue Expression Levels of YKL-40 in Renal Cell Cancer. J Urol 2016;195:1120-5. [PMID: 26454102 DOI: 10.1016/j.juro.2015.09.084] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
14 Lee YS, Yu JE, Kim KC, Lee DH, Son DJ, Lee HP, Jung JK, Kim ND, Ham YW, Yun J, Han SB, Hong JT. A small molecule targeting CHI3L1 inhibits lung metastasis by blocking IL-13Rα2-mediated JNK-AP-1 signals. Mol Oncol 2021. [PMID: 34758182 DOI: 10.1002/1878-0261.13138] [Reference Citation Analysis]
15 Cheng D, Sun Y, He H. Diagnostic role of circulating YKL-40 in endometrial carcinoma patients: a meta-analysis of seven related studies. Med Oncol 2014;31. [DOI: 10.1007/s12032-014-0326-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
16 Luo D, Chen H, Lu P, Li X, Long M, Peng X, Huang M, Huang K, Lin S, Tan L, Zhu Y, Chen Z, Ouyang N, Li H. CHI3L1 overexpression is associated with metastasis and is an indicator of poor prognosis in papillary thyroid carcinoma. Cancer Biomark 2017;18:273-84. [PMID: 28009325 DOI: 10.3233/CBM-160255] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
17 Cantó E, Tintoré M, Villar LM, Costa C, Nurtdinov R, Álvarez-cermeño JC, Arrambide G, Reverter F, Deisenhammer F, Hegen H, Khademi M, Olsson T, Tumani H, Rodríguez-martín E, Piehl F, Bartos A, Zimova D, Kotoucova J, Kuhle J, Kappos L, García-merino JA, Sánchez AJ, Saiz A, Blanco Y, Hintzen R, Jafari N, Brassat D, Lauda F, Roesler R, Rejdak K, Papuc E, de Andrés C, Rauch S, Khalil M, Enzinger C, Galimberti D, Scarpini E, Teunissen C, Sánchez A, Rovira A, Montalban X, Comabella M. Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes. Brain 2015;138:918-31. [DOI: 10.1093/brain/awv017] [Cited by in Crossref: 97] [Cited by in F6Publishing: 90] [Article Influence: 13.9] [Reference Citation Analysis]
18 Xiao XQ, Hassanein T, Li QF, Liu W, Zheng YH, Chen J. YKL-40 expression in human hepatocellular carcinoma: a potential biomarker? Hepatobiliary Pancreat Dis Int 2011;10:605-10. [PMID: 22146624 DOI: 10.1016/s1499-3872(11)60103-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
19 Xiao T, Bao L, Ji H. Finding biomarkers for non-small cell lung cancer diagnosis and prognosis. Front Biol 2012;7:14-23. [DOI: 10.1007/s11515-011-1163-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
20 Kim HR, Jun CD, Lee KS, Cho JH, Jeong ET, Yang SH, Lee YJ, Park DS. Levels of YKL-40 in pleural effusions and blood from patients with pulmonary or pleural disease. Cytokine 2012;58:336-43. [PMID: 22480951 DOI: 10.1016/j.cyto.2012.03.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
21 Huang WS, Lin H, Yeh C, Chen L, Chou Y, Yang S, Liu Y. Correlation of Chitinase 3-Like 1 Single Nucleotide Polymorphisms with Hepatocellular Carcinoma in Taiwan. Int J Med Sci 2017;14:136-42. [DOI: 10.7150/ijms.17754] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
22 Jefri M, Huang YN, Huang WC, Tai CS, Chen WL. YKL-40 regulated epithelial-mesenchymal transition and migration/invasion enhancement in non-small cell lung cancer. BMC Cancer 2015;15:590. [PMID: 26275425 DOI: 10.1186/s12885-015-1592-3] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 5.1] [Reference Citation Analysis]
23 Bian B, Li L, Yang J, Liu Y, Xie G, Zheng Y, Zeng L, Zeng J, Shen L. Prognostic value of YKL-40 in solid tumors: a meta-analysis of 41 cohort studies. Cancer Cell Int 2019;19:259. [PMID: 31624472 DOI: 10.1186/s12935-019-0983-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
24 Fan JT, Si XH, Liao Y, Shen P. The diagnostic and prognostic value of serum YKL-40 in endometrial cancer. Arch Gynecol Obstet 2013;287:111-5. [PMID: 22945838 DOI: 10.1007/s00404-012-2546-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
25 Mack I, Hector A, Ballbach M, Kohlhäufl J, Fuchs KJ, Weber A, Mall MA, Hartl D. The role of chitin, chitinases, and chitinase-like proteins in pediatric lung diseases. Mol Cell Pediatr 2015;2:3. [PMID: 26542293 DOI: 10.1186/s40348-015-0014-6] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 5.0] [Reference Citation Analysis]
26 Liu T, Larionova I, Litviakov N, Riabov V, Zavyalova M, Tsyganov M, Buldakov M, Song B, Moganti K, Kazantseva P, Slonimskaya E, Kremmer E, Flatley A, Klüter H, Cherdyntseva N, Kzhyshkowska J. Tumor-associated macrophages in human breast cancer produce new monocyte attracting and pro-angiogenic factor YKL-39 indicative for increased metastasis after neoadjuvant chemotherapy. Oncoimmunology 2018;7:e1436922. [PMID: 29872578 DOI: 10.1080/2162402X.2018.1436922] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
27 Saengboonmee C, Sawanyawisuth K, Chamgramol Y, Wongkham S. Prognostic biomarkers for cholangiocarcinoma and their clinical implications. Expert Rev Anticancer Ther 2018;18:579-92. [PMID: 29676221 DOI: 10.1080/14737140.2018.1467760] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
28 Yan C, Ding X, Wu L, Yu M, Qu P, Du H. Stat3 downstream gene product chitinase 3-like 1 is a potential biomarker of inflammation-induced lung cancer in multiple mouse lung tumor models and humans. PLoS One 2013;8:e61984. [PMID: 23613996 DOI: 10.1371/journal.pone.0061984] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
29 Holmgaard DB, Mygind LH, Titlestad IL, Madsen H, Pedersen SS, Johansen JS, Pedersen C. Plasma YKL-40 and all-cause mortality in patients with chronic obstructive pulmonary disease. BMC Pulm Med 2013;13:77. [PMID: 24373580 DOI: 10.1186/1471-2466-13-77] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
30 Pan JJ, Ge YS, Xu GL, Jia WD, Liu WF, Li JS, Liu WB. The expression of chitinase 3-like 1: a novel prognostic predictor for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2013;139:1043-1054. [PMID: 23525579 DOI: 10.1007/s00432-013-1415-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
31 Liu X, Zhang Y, Zhu Z, Ha M, Wang Y. Elevated pretreatment serum concentration of YKL-40: an independent prognostic biomarker for poor survival in patients with colorectal cancer. Med Oncol 2014;31:85. [PMID: 24996799 DOI: 10.1007/s12032-014-0085-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
32 Tschirdewahn S, Reis H, Niedworok C, Nyirady P, Szendröi A, Schmid KW, Shariat SF, Kramer G, vom Dorp F, Rübben H, Szarvas T. Prognostic effect of serum and tissue YKL-40 levels in bladder cancer. Urologic Oncology: Seminars and Original Investigations 2014;32:663-9. [DOI: 10.1016/j.urolonc.2014.02.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
33 Zhang S, Zhao YF, Zhang MZ, Wu XL. The diagnostic value of tumor markers in bronchoalveolar lavage fluid for the peripheral pulmonary carcinoma. Clin Respir J 2017;11:481-8. [PMID: 26260621 DOI: 10.1111/crj.12362] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
34 Ma B, Akosman B, Kamle S, Lee CM, He CH, Koo JS, Lee CG, Elias JA. CHI3L1 regulates PD-L1 and anti-CHI3L1-PD-1 antibody elicits synergistic antitumor responses. J Clin Invest 2021;131:e137750. [PMID: 34720089 DOI: 10.1172/JCI137750] [Reference Citation Analysis]
35 Schultz NA, Johansen JS. YKL-40-A Protein in the Field of Translational Medicine: A Role as a Biomarker in Cancer Patients? Cancers (Basel) 2010;2:1453-91. [PMID: 24281168 DOI: 10.3390/cancers2031453] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 3.3] [Reference Citation Analysis]
36 Kjaergaard AD, Nordestgaard BG, Johansen JS, Bojesen SE. Observational and genetic plasma YKL-40 and cancer in 96,099 individuals from the general population. Int J Cancer 2015;137:2696-704. [PMID: 26095694 DOI: 10.1002/ijc.29638] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
37 Shaker OG, Helmy HS. Circulating Bone-related Markers and YKL-40 Versus HER2 and TOPO2a in Bone Metastatic and Nonmetastatic Breast Cancer: Diagnostic Implications. Clin Breast Cancer 2018;18:e321-8. [PMID: 28645722 DOI: 10.1016/j.clbc.2017.05.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
38 Tanrıverdi Z, Meteroglu F, Yüce H, Şenyiğit A, Işcan M, Unüvar S. The usefulness of biomarkers in diagnosis of asbestos-induced malignant pleural mesothelioma. Hum Exp Toxicol 2021;:9603271211017324. [PMID: 33998299 DOI: 10.1177/09603271211017324] [Reference Citation Analysis]
39 Yip AY, Ong EY, Chow LW. Translational research to realize the full potential of novel agents--an opportunity for vinflunine? Expert Opin Drug Saf 2012;11 Suppl 1:S5-8. [PMID: 21957991 DOI: 10.1517/14740338.2011.624092] [Reference Citation Analysis]
40 Zheng X, Xing S, Liu XM, Liu W, Liu D, Chi PD, Chen H, Dai SQ, Zhong Q, Zeng MS. Establishment of using serum YKL-40 and SCCA in combination for the diagnosis of patients with esophageal squamous cell carcinoma. BMC Cancer. 2014;14:490. [PMID: 25001061 DOI: 10.1186/1471-2407-14-490] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
41 Zoheiry MM, Hasan SA, El-Ahwany E, Nagy FM, Taleb HA, Nosseir M, Magdy M, Meshaal S, El-Talkawy MD, Raafat I. Serum Markers of Epithelial Mesenchymal Transition as Predictors of HCV-induced Liver Fibrosis, Cirrhosis and Hepatocellular Carcinoma. Electron Physician 2015;7:1626-37. [PMID: 26816590 DOI: 10.19082/1626] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]